標(biāo)題: Titlebook: Cancer Therapy; Monoclonal Antibodie Hans G. Beger (Professor of Surgery),Markus Büchle Conference proceedings 1989 Springer-Verlag Berlin [打印本頁] 作者: Denial 時(shí)間: 2025-3-21 17:19
書目名稱Cancer Therapy影響因子(影響力)
書目名稱Cancer Therapy影響因子(影響力)學(xué)科排名
書目名稱Cancer Therapy網(wǎng)絡(luò)公開度
書目名稱Cancer Therapy網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Cancer Therapy被引頻次
書目名稱Cancer Therapy被引頻次學(xué)科排名
書目名稱Cancer Therapy年度引用
書目名稱Cancer Therapy年度引用學(xué)科排名
書目名稱Cancer Therapy讀者反饋
書目名稱Cancer Therapy讀者反饋學(xué)科排名
作者: 無聊點(diǎn)好 時(shí)間: 2025-3-21 22:17 作者: larder 時(shí)間: 2025-3-22 02:13
https://doi.org/10.1007/978-981-19-5570-9lonal antibodies has rapidly led to clinical investigations. Experience with monoclonal antibodies in the treatment of patients with melanoma is limited [4, 9, 10, 12, 13, 17, 19] because only small groups of patients have been treated so far. According to these studies, treatment with ganglioside antibodies appears most promising.作者: NOMAD 時(shí)間: 2025-3-22 05:04 作者: Munificent 時(shí)間: 2025-3-22 11:03 作者: Figate 時(shí)間: 2025-3-22 16:41
Mab 17-1A Used for Therapy of Patients with Metastatic Colorectal Carcinomasially on fetal cells. On normal mature cells, TAA might be detected only by highly sensitive techniques or after manipulation of the cell membrane. On malignant cells, TAA are often re-expressed in high concentrations. Such antigens can be exploited not only for diagnostic purposes, but also as targets for immunotherapy.作者: Figate 時(shí)間: 2025-3-22 17:07
Immunotherapy of Malignant Melanomaslonal antibodies has rapidly led to clinical investigations. Experience with monoclonal antibodies in the treatment of patients with melanoma is limited [4, 9, 10, 12, 13, 17, 19] because only small groups of patients have been treated so far. According to these studies, treatment with ganglioside antibodies appears most promising.作者: 坦白 時(shí)間: 2025-3-22 21:34
The Role of Interferon in the Management of Patients with Hairy Cell Leukemia and Multiple Myeloma of cancer, particularly since in 1981 highly purified material produced by recombinant DNA technology has become available in addition to natural IFNs [25, 51, 59]. So far, the most impressive clinical results have been achieved in hematologic disorders, especially in hairy cell leukemia [26, 41, 54].作者: terazosin 時(shí)間: 2025-3-23 02:08 作者: crease 時(shí)間: 2025-3-23 06:47 作者: Ergots 時(shí)間: 2025-3-23 11:35
978-3-642-73723-7Springer-Verlag Berlin Heidelberg 1989作者: BINGE 時(shí)間: 2025-3-23 15:59
https://doi.org/10.1007/978-3-030-62171-1l targets for the diagnosis and therapy of cancer. Research efforts in this area have intensified during the last decade because of the availability of monoclonal antibodies and the rapid emergence of increasingly sophisticated technologies of gene cloning. The relatively slow progress in the clinic作者: altruism 時(shí)間: 2025-3-23 18:48 作者: BULLY 時(shí)間: 2025-3-24 01:49
https://doi.org/10.1007/978-3-663-10899-3[1]. Monoclonal antibody technology [2] enables an antibody-producing lymphocyte to be fused with a cultured myeloma cell, thus producing a hybridoma that secretes a specific monoclonal antibody. It is now possible to manufacture large quantities of immunoglobulins with unique specificity. Monoclona作者: 一再遛 時(shí)間: 2025-3-24 04:40 作者: forestry 時(shí)間: 2025-3-24 07:50 作者: dagger 時(shí)間: 2025-3-24 11:48
https://doi.org/10.1007/978-3-031-21622-0ially on fetal cells. On normal mature cells, TAA might be detected only by highly sensitive techniques or after manipulation of the cell membrane. On malignant cells, TAA are often re-expressed in high concentrations. Such antigens can be exploited not only for diagnostic purposes, but also as targ作者: Nuance 時(shí)間: 2025-3-24 18:35 作者: 豐滿中國 時(shí)間: 2025-3-24 19:41 作者: PANIC 時(shí)間: 2025-3-25 02:06
Introductory Remarks at the Overview Session. The molecular basis of the differential sensitivity of cancer tissues for these drugs as compared with normal tissues remains, however, largely undefined. It has been postulated that differences in the kinetics of cell proliferation are the basis of this differential sensitivity. This has been dem作者: 不理會(huì) 時(shí)間: 2025-3-25 04:26
J. I. Sprent,F. R. Minchin,R. Parsonsthe treatment of advanced melanoma in 24 patients [1]. In this report, we present results on the first 30 patients treated with this regimen. Our rationale for giving low-dose CY was to inhibit suppressor T cells, the number and activity of which might be increased by IL-2, thereby possibly preventi作者: LAPSE 時(shí)間: 2025-3-25 11:34 作者: Uncultured 時(shí)間: 2025-3-25 15:27 作者: 親愛 時(shí)間: 2025-3-25 16:11
New Horizons in Occultation Researchferentiation and mature myeloid cell function. With the availability of large quantities of these agents in recombinant form [1–4], it was soon demonstrated that they could as well increase the rate of myeloid cell proliferation in vivo and increase blood myeloid cell numbers [5–8]. The most obvious作者: 壯麗的去 時(shí)間: 2025-3-25 23:17
New Horizons in Occultation Research of cancer, particularly since in 1981 highly purified material produced by recombinant DNA technology has become available in addition to natural IFNs [25, 51, 59]. So far, the most impressive clinical results have been achieved in hematologic disorders, especially in hairy cell leukemia [26, 41, 5作者: 分散 時(shí)間: 2025-3-26 02:30 作者: Evolve 時(shí)間: 2025-3-26 04:30
New Horizons in Occultation Researchkes stages, the 5-year-survival rates never exceeded 50% [1, 2]. Surgical progress has been restricted to the development of sphincter-saving procedures for rectal cancer at low levels [3–6]. However, an improvement in the prognosis of colorectal cancer patients should not be expected from surgery a作者: fulcrum 時(shí)間: 2025-3-26 10:56
J. I. Sprent,F. R. Minchin,R. Parsonsng an increase in the number of helper and cytolytic T cells and in lymphokine-activated killer (LAK) cells as well. The dose of IL-2 was chosen to be at or near the projected maximum tolerated single dose level, as estimated from Phase I data.作者: 施魔法 時(shí)間: 2025-3-26 15:06 作者: 因無茶而冷淡 時(shí)間: 2025-3-26 17:46
Conference proceedings 1989nd radiotherapy with new approaches in the field of immunotherapy can result in an improved treatment modality. Immunotherapy in this context consists of therapy with monoclonal antibodies, hematopoietic growth factors and other lymphokines. Results of early clinical trials with IL-2, GM-CSF and mon作者: deriver 時(shí)間: 2025-3-26 22:14
l chemo- and radiotherapy with new approaches in the field of immunotherapy can result in an improved treatment modality. Immunotherapy in this context consists of therapy with monoclonal antibodies, hematopoietic growth factors and other lymphokines. Results of early clinical trials with IL-2, GM-C作者: Magnitude 時(shí)間: 2025-3-27 04:57
J. I. Sprent,F. R. Minchin,R. Parsonsoned from the HUT 102 cell line, and using a yeast expression system, recombinant human GM-CSF (rhGM-CSF) has been produced and purified to homogeneity [4]. It has also been possible to clone rhGM-CSF from the human Mo-cell line [5].作者: 健談的人 時(shí)間: 2025-3-27 06:03 作者: intrude 時(shí)間: 2025-3-27 12:45 作者: Ceramic 時(shí)間: 2025-3-27 17:07 作者: CANDY 時(shí)間: 2025-3-27 18:08 作者: condone 時(shí)間: 2025-3-27 23:25
Immunochemotherapy of Cancer: A Perspectiverly by applying immunoconjugates. Among these conjugates, those made between monoclonal antibodies and either chemotherapeutic drugs, radionuclides, or plant toxins represent the three major categories.作者: modifier 時(shí)間: 2025-3-28 04:52
Immunotherapy of Pancreatic Cancer with Monoclonal Antibody BW 494: Results from a Multicentric Phaspatients (0.4% with 5-year survival) were still alive [2]. Only about 10%–20% of the patients are able to undergo a potentially curative operation in the form of a partial or total pancreatoduodenectomy [1, 2, 6–9]. The therapeutic dilemma is further characterized by the lack of response to chemo- or radiotherapy [10–15].作者: 喊叫 時(shí)間: 2025-3-28 10:05
Interaction of Monoclonal Antibodies with Biological Response Modifiers and Cytostaticsdrug combinations tested result in similar response rates, (b) that second- or third-line therapy may be active even in the event of nonresponse in the first trial, and (c) that we do not have clinical parameters indicating tumor sensitivity or insensitivity before therapy is initiated.作者: 可卡 時(shí)間: 2025-3-28 14:13
A. L?scher,K.B. Lauritsen,M. S?rensens, and we (Digel et al. 1988) have shown recently that recombinant TNF-α stimulates the growth of purified B cells from patients with B-chronic lymphocytic leukemia (B-CLL). Based on these findings, we hypothesize that TNF is produced in B-cell disorders like HCL and that TNF may stimulate the growth of hairy cells (HC).作者: staging 時(shí)間: 2025-3-28 16:02 作者: 天真 時(shí)間: 2025-3-28 19:33
Conference proceedings 1989 The use of hormones, such as LH-RH agonists, allows hormone-dependent tumors such as prostatic and breast cancer to be treated without strong adverse reactions. These recent findings give the reader insight into exciting therapeutic directions made possible by such combined, rather than single, modalities.作者: 偏見 時(shí)間: 2025-3-28 23:21
K. K. Kapiyangoda,R. H. Surangi Lewistopes on CEA [3, 6] and not cross-reactive with epitopes on NCAs or Y- or X-type carbohydrate moieties on CEA [21] are primarily confronted with high amounts of circulating CEA after their i. v. injection into the patient. The following in vitro experiments were conducted to explain why successful i作者: 畫布 時(shí)間: 2025-3-29 04:32
https://doi.org/10.1007/978-3-663-10899-3clinical results have been reported by many workers [3–6]. Other potential uses of monoclonal antibodies include the delivery of chemotherapy [7], toxins [8] or radionuclides [9–13] to specifically destroy tumour cells.作者: Ebct207 時(shí)間: 2025-3-29 10:25
Introductory Remarks at the Overview Sessiond largely disappointing, and cure rates been stagnating, especially for the more frequent cancers, such as lung, breast, and colon cancer [1]. Therefore, current researchers are looking for new concepts of cancer treatment based on a more profound understanding of tumor biology.作者: 預(yù)測(cè) 時(shí)間: 2025-3-29 15:22 作者: 確定無疑 時(shí)間: 2025-3-29 18:39
New Horizons in Occultation Researchte function [9–13], and such activated cells can specifically recognize and lyse tumor cells [14–17], another potential application of these agents might be as antitumor drugs which mediate their antitumor effects through activation of effector cell function. To evaluate the potential of CSFs in thi作者: 不怕任性 時(shí)間: 2025-3-29 22:29 作者: biopsy 時(shí)間: 2025-3-30 01:07
Quantitative Considerations Supporting the Irrelevance of Circulating Serum Carcinoembryonic Antigentopes on CEA [3, 6] and not cross-reactive with epitopes on NCAs or Y- or X-type carbohydrate moieties on CEA [21] are primarily confronted with high amounts of circulating CEA after their i. v. injection into the patient. The following in vitro experiments were conducted to explain why successful i作者: ARC 時(shí)間: 2025-3-30 06:49
Radioimmunotherapy with Iodine 131-Labelled Antibodies in Ovarian, Colonic and Brain Tumoursclinical results have been reported by many workers [3–6]. Other potential uses of monoclonal antibodies include the delivery of chemotherapy [7], toxins [8] or radionuclides [9–13] to specifically destroy tumour cells.作者: 輕浮女 時(shí)間: 2025-3-30 09:30 作者: 信條 時(shí)間: 2025-3-30 15:01 作者: 慷慨援助 時(shí)間: 2025-3-30 19:48
A Phase Ib Evaluation of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factorte function [9–13], and such activated cells can specifically recognize and lyse tumor cells [14–17], another potential application of these agents might be as antitumor drugs which mediate their antitumor effects through activation of effector cell function. To evaluate the potential of CSFs in thi作者: 話 時(shí)間: 2025-3-30 21:07 作者: 絕種 時(shí)間: 2025-3-31 02:47
